<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240821</url>
  </required_header>
  <id_info>
    <org_study_id>IND 133013 Extension Study</org_study_id>
    <nct_id>NCT04240821</nct_id>
  </id_info>
  <brief_title>Theophylline for Treatment of Pseudohypoparathyroidism</brief_title>
  <official_title>Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ashley Shoemaker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized&#xD;
      by early-onset obesity, short stature, hormone resistance and cognitive impairment. This&#xD;
      phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor,&#xD;
      in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve&#xD;
      glucose tolerance and decrease hormone resistance in children and young adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Objectives&#xD;
&#xD;
        1. The primary objective of this study is to evaluate the long-term safety of theophylline&#xD;
           in patients with PHP.&#xD;
&#xD;
        2. The secondary objectives of this study are to evaluate changes in BMI, hormone&#xD;
           resistance and epiphyseal closure associated with theophylline treatment of patients&#xD;
           with PHP.&#xD;
&#xD;
      Study Design The proposed study is a single center, 24-month open label extension clinical&#xD;
      trial for patients with PHP who complete the randomized clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label extension study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment-emergent adverse events will be compared before and during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>24 months</time_frame>
    <description>Change in BMI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pseudohypoparathyroidism</condition>
  <condition>Pseudohypoparathyroidism Type 1a</condition>
  <condition>Albright Hereditary Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Open-label theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral theophylline - either once daily capsule or q6h elixir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline ER</intervention_name>
    <description>Oral theophylline</description>
    <arm_group_label>Open-label theophylline</arm_group_label>
    <other_name>Theophylline elixir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Successful completion of the randomized clinical trial &quot;Phase 2 Study of&#xD;
             Theophylline Treatment of Pseudohypoparathyroidism IND 133103 (11/1/2016)&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of a seizure disorder unrelated to hypocalcemia&#xD;
&#xD;
          2. History of a cardiac arrhythmia (not including bradycardia)&#xD;
&#xD;
          3. Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT &gt;3x upper&#xD;
             limit of normal)&#xD;
&#xD;
          4. Congestive heart failure&#xD;
&#xD;
          5. Current cigarette use or alcohol abuse&#xD;
&#xD;
          6. Pregnancy or intention to become pregnant during the next year&#xD;
&#xD;
          7. Active peptic ulcer disease&#xD;
&#xD;
          8. Current use of medications known to effect theophylline levels&#xD;
&#xD;
          9. History of hypersensitivity to theophylline or other medication components&#xD;
&#xD;
         10. Unable to comply with study procedures in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Shoemaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/pseudohypoparathyroidism</url>
    <description>Research Group Facebook Page</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Ashley Shoemaker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>University faculty</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

